Organogenesis receives FDA 510(k) clearance to market rotator cuff repair patch.
The product is comprised of Organogenesis' FortaFlex bioengineered collagen matrix. The company says the product is the first developed under its collaboration with Biomet, Inc., who will market the product. Under terms of the agreement, Organogenesis will receive a transfer price based on a percentage of the product's selling price.
Each year there are more than 200,000 rotator cuff repair procedures. Organogenesis says its rotator cuff patch provides a resorbable scaffold for the reinforcement of soft tissues which are repaired by sutures and suture anchors during rotator cuff surgery and has been optimized for the strength and tissue interaction requirements for this use.
Contact: Laurie Doyle - (781) 575-0775; Web sites: www.organogenesis.com. or www.biomet.com.
|Printer friendly Cite/link Email Feedback|
|Comment:||Organogenesis receives FDA 510(k) clearance to market rotator cuff repair patch.|
|Article Type:||Brief Article|
|Date:||Mar 31, 2002|
|Previous Article:||Gilead submits NDA to FDA for chronic hepatitis treatment, launches early access program.|
|Next Article:||DOR BioPharma's GVHD treatment receives first European Orphan Medicinal Product designation.|
|FDA approves Novartis' Apligraf for treatment of diabetic foot ulcers.|
|ARTHROCARE GETS FDA CLEARANCE FOR ALL-PEEK IMPLANT SYSTEM.|